pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,756 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT834Endpoints640BioPharma Dive243onclive165BioSpace98Fierce Biotech96raps39globenewswire health28fda recalls
therapy area
allOncology5008Rare Disease855Cardiology803Hematology772Immunology736Psychiatry & CNS582Pulmonology
  • A CAR-T biotech’s dramatic turnaround, and drugmakers’ tactics to drive more scripts
    This week on "The Readout LOUD": a CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts. Listen now.
    STAT · 3mo ago↗ source
  • STAT+: Trump celebrates closing first round of drug pricing deals, promises more ahead
    A deal with Regeneron was the last of 17 initially sought by the White House.
    STAT · 3mo ago↗ source
  • FDA approves Regeneron’s hearing loss gene therapy
    Otarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA’s “national priority” voucher program and will be offered to eligible patients…
    BioPharma Dive · 3mo ago↗ source
← prev
page 70 of 71
next →
24
fda press21
fda medwatch18
573
Vaccines517
Endocrinology & Metabolism293
Ophthalmology265
Infectious Disease253
Nephrology239
  • FDA approves Regeneron's hearing loss gene therapy Otarmeni
    Regeneron has won the first-ever FDA approval for a gene therapy to treat a rare type of inherited hearing loss, and the company plans to offer the treatment for free in the US, though that ...
    Endpoints · 3mo ago↗ source
  • Substance use disorder biotech Tempero to close after earlier 'serious' safety event
    Tempero Bio, a drug developer that had big ambitions to shake up the treatment of substance use disorders, is winding down operations, Endpoints News has learned. The shutdown comes after a "seriou…
    Endpoints · 3mo ago↗ source
  • Heart’s beat may help it beat cancer, mouse research suggests
    The constant pressure that the heart is under from beating thousands of times a day may create an environment hostile to cancers
    STAT · 3mo ago↗ source
  • STAT+: Trump’s boosting of psychedelics, cannabis signal a new era in GOP drug policy
    The Trump administration, in a stark departure from the "Just Say No" era, is funding psychedelics research and rescheduling marijuana.
    STAT · 3mo ago↗ source
  • Post-Hoc Live: MAHA, the new Trump CDC pick and RFK's vaccine agenda
    MAHA’s sway over HHS could face a fresh test now that President Trump has a new pick for CDC director: Erica Schwartz, a former deputy surgeon general. The position has been empty ...
    Endpoints · 3mo ago↗ source
  • Novartis' radioligand therapy Lutathera could soon face generic competition
    The radioligand field is on the cusp of a major competitive moment, as a rival looks to bring the first generic to a market that’s been dominated by Novartis. Radioligand therapy aims to bring the ...
    Endpoints · 3mo ago↗ source
  • Drugmaker AbbVie chooses North Carolina for $1.4B manufacturing campus
    The 185-acre site will be the company’s largest single investment to date, with a focus on small-volume parenteral products like vials and prefilled syringes.
    BioPharma Dive · 3mo ago↗ source
  • STAT+: Legislatures in Colorado and Virginia resist moves to constrain drug affordability boards
    Legislators in two states are resisting efforts to restrict prescription drug affordability boards.
    STAT · 3mo ago↗ source
  • Opinion: Dropping the flu vaccine requirement puts U.S. military readiness at risk
    Since the 1918 pandemic, the military has acknowledged the threat of influenza. Now that’s changing.
    STAT · 3mo ago↗ source
  • STAT+: Sanofi research priorities in flux as new CEO logs in
    A gene therapy for deafness, all eyes on Erasca, and other biotech news from The Readout
    STAT · 3mo ago↗ source
  • Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs
    On a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines could bank more than $9 billion annually.
    BioPharma Dive · 3mo ago↗ source
  • David Reese to retire from Amgen
    Longtime Amgen leader David Reese is retiring at the end of June, Amgen announced Wednesday evening. Reese, 63, currently serves as chief technology officer, a role he created at Amgen in 2023 ...
    Endpoints · 3mo ago↗ source
  • Sanofi posts upbeat sales as R&D pressure builds
    A string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over. But positive first-quarter earnings provided the company with a needed boost.
    BioPharma Dive · 3mo ago↗ source
  • The Godmother of Silicon Valley is helping launch an AI healthcare residency program
    Esther Wojcicki wants to help healthcare startup co-founders get along. That might seem simple, but co-founder disagreements are a big contributor to startups falling apart, she said. She’s got the…
    Endpoints · 3mo ago↗ source
  • Novo's pill for kids; Altimmune’s $225M offering; Merck teams with Google Cloud
    Novo Nordisk’s GLP-1 pill works in kids with diabetes: Type 2 diabetes patients aged 10 to 17 who took Rybelsus for about six months had a statistically significant 0.83% cut in their blood sugar l…
    Endpoints · 3mo ago↗ source
  • Amneal to buy a biosimilar company; Samsung Bio workers protest
    Plus, news about Avonik, a supply chain transparency bill and Nucleus RadioPharma: 💰 Amneal Pharmaceuticals to acquire biosimilar maker for $375M upfront: The generics and specialty drugmaker is s…
    Endpoints · 3mo ago↗ source
  • Endpoints wins Neal Awards for Trump and gene editing coverage, JPM event
    Endpoints News was recognized with three 2026 Neal Awards for its coverage of the drug industry's relationship with the Trump administration, a three-part series on the future of CRISPR gene editin…
    Endpoints · 3mo ago↗ source
  • Gravity Rail raises $2.75M from Redesign Health for AI patient communication
    A startup that helps healthcare providers handle calls, texts and follow-ups with patients using AI has raised seed funding, Endpoints News learned exclusively. Gravity Rail handles the process of…
    Endpoints · 3mo ago↗ source
  • Roche says its investigational breast cancer pill could outsell Herceptin
    Roche still has high sales hopes for its breast cancer pill giredestrant despite the drug’s failure in a first-line trial earlier this year. CEO Thomas Schinecker said Thursday that the drug could ...
    Endpoints · 3mo ago↗ source
  • Sanofi defends Garijo appointment, says it is 'fully committed' to immunology
    Sanofi’s first-quarter earnings call with the media on Thursday was an exercise in redirecting the narrative before its new CEO steps in next week. CFO François-Xavier Roger defended the company’s…
    Endpoints · 3mo ago↗ source
  • OpenAI's head of health lays out the AI giant’s healthcare ambitions
    OpenAI is launching ChatGPT for Clinicians, a free tool for doctors, nurse practitioners, physician assistants and pharmacists. It’s the latest product the AI giant has launched within healthcare,…
    Endpoints · 3mo ago↗ source
  • AbbVie's $1.4B North Carolina manufacturing site to finish during Trump's term
    AbbVie has provided new details about its $100 billion pledge to the US, budgeting $1.4 billion for its first manufacturing campus in North Carolina. Construction of the 185-acre campus in Durham,…
    Endpoints · 3mo ago↗ source